A detailed history of Murphy, Middleton, Hinkle & Parker, Inc. transactions in Amgen Inc stock. As of the latest transaction made, Murphy, Middleton, Hinkle & Parker, Inc. holds 3,636 shares of AMGN stock, worth $1.17 Million. This represents 0.63% of its overall portfolio holdings.

Number of Shares
3,636
Previous 3,639 0.08%
Holding current value
$1.17 Million
Previous $1.14 Million 2.99%
% of portfolio
0.63%
Previous 0.66%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 15, 2024

SELL
$309.38 - $337.38 $928 - $1,012
-3 Reduced 0.08%
3,636 $1.17 Million
Q2 2024

Jul 16, 2024

SELL
$262.75 - $319.31 $28,902 - $35,124
-110 Reduced 2.93%
3,639 $1.14 Million
Q4 2023

Jan 24, 2024

SELL
$255.7 - $288.46 $767 - $865
-3 Reduced 0.08%
3,749 $1.08 Million
Q3 2023

Oct 03, 2023

SELL
$218.65 - $271.46 $41,543 - $51,577
-190 Reduced 4.82%
3,752 $1.01 Million
Q4 2022

Jan 17, 2023

SELL
$229.03 - $291.01 $8,016 - $10,185
-35 Reduced 0.88%
3,942 $1.04 Million
Q3 2022

Oct 07, 2022

SELL
$224.46 - $253.15 $24,690 - $27,846
-110 Reduced 2.69%
3,977 $896,000
Q3 2021

Oct 07, 2021

SELL
$212.27 - $248.7 $849 - $994
-4 Reduced 0.1%
4,087 $869,000
Q2 2021

Jul 13, 2021

BUY
$233.58 - $259.14 $8,642 - $9,588
37 Added 0.91%
4,091 $997,000
Q1 2021

Apr 08, 2021

SELL
$221.91 - $258.6 $7,101 - $8,275
-32 Reduced 0.78%
4,054 $1.01 Million
Q4 2020

Jan 12, 2021

SELL
$216.38 - $257.67 $25,100 - $29,889
-116 Reduced 2.76%
4,086 $939,000
Q3 2020

Oct 13, 2020

SELL
$234.65 - $260.95 $41,533 - $46,188
-177 Reduced 4.04%
4,202 $1.07 Million
Q1 2019

Apr 17, 2019

SELL
$180.87 - $203.88 $7,777 - $8,766
-43 Reduced 0.97%
4,379 $832,000
Q2 2018

Jul 13, 2018

BUY
$166.05 - $186.51 $734,273 - $824,747
4,422 New
4,422 $816,000

Others Institutions Holding AMGN

About AMGEN INC


  • Ticker AMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 534,931,008
  • Market Cap $172B
  • Description
  • Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...
More about AMGN
Track This Portfolio

Track Murphy, Middleton, Hinkle & Parker, Inc. Portfolio

Follow Murphy, Middleton, Hinkle & Parker, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Murphy, Middleton, Hinkle & Parker, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Murphy, Middleton, Hinkle & Parker, Inc. with notifications on news.